Cogent Biosciences (COGT) Competitors $8.89 +0.69 (+8.41%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends COGT vs. IMVT, CRNX, RNA, PTCT, RYTM, DNLI, XENE, ACAD, VCEL, and MORShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Immunovant Crinetics Pharmaceuticals Avidity Biosciences PTC Therapeutics Rhythm Pharmaceuticals Denali Therapeutics Xenon Pharmaceuticals ACADIA Pharmaceuticals Vericel MorphoSys Cogent Biosciences (NASDAQ:COGT) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends. Do analysts rate COGT or IMVT? Cogent Biosciences presently has a consensus target price of $14.33, suggesting a potential upside of 80.98%. Immunovant has a consensus target price of $47.00, suggesting a potential upside of 102.57%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Immunovant 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Which has stronger earnings & valuation, COGT or IMVT? Immunovant is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$2.48-3.19ImmunovantN/AN/A-$259.34M-$2.22-10.45 Do institutionals & insiders have more ownership in COGT or IMVT? 47.1% of Immunovant shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by company insiders. Comparatively, 5.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor COGT or IMVT? In the previous week, Immunovant had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 16 mentions for Immunovant and 7 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.64 beat Immunovant's score of 0.36 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, COGT or IMVT? Cogent Biosciences has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Is COGT or IMVT more profitable? Immunovant's return on equity of -56.40% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Immunovant N/A -56.40%-52.03% Does the MarketBeat Community believe in COGT or IMVT? Cogent Biosciences received 164 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.99% of users gave Immunovant an outperform vote while only 70.59% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes28870.59% Underperform Votes12029.41% ImmunovantOutperform Votes12477.99% Underperform Votes3522.01% SummaryImmunovant beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$981.99M$6.61B$5.44B$9.25BDividend YieldN/A2.94%5.36%3.96%P/E Ratio-3.589.9089.0617.54Price / SalesN/A339.391,244.4288.52Price / CashN/A66.9244.6537.70Price / Book3.875.185.044.74Net Income-$192.41M$154.67M$117.90M$224.54M7 Day Performance9.35%3.65%3.02%1.87%1 Month Performance14.56%2.31%4.34%4.57%1 Year Performance92.01%6.81%27.06%22.24% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences1.6667 of 5 stars$8.89+8.4%$14.33+61.2%+74.5%$981.99MN/A-3.5880IMVTImmunovant2.1829 of 5 stars$23.86+0.3%$47.00+97.0%-42.0%$3.50BN/A-10.75120Analyst RevisionCRNXCrinetics Pharmaceuticals3.9257 of 5 stars$37.35+2.4%$74.40+99.2%+5.5%$3.46B$4.01M-10.01210Analyst UpgradeAnalyst RevisionNews CoverageRNAAvidity Biosciences1.1899 of 5 stars$28.92+2.2%$65.80+127.5%+190.1%$3.45B$9.56M-10.04190Analyst ForecastAnalyst RevisionNews CoveragePTCTPTC Therapeutics4.0769 of 5 stars$43.84+1.8%$55.00+25.5%+65.3%$3.38B$900.66M-7.381,410Analyst RevisionNews CoverageHigh Trading VolumeRYTMRhythm Pharmaceuticals4.0892 of 5 stars$54.54-0.2%$68.09+24.8%+37.2%$3.35B$77.43M-12.60140DNLIDenali Therapeutics4.4056 of 5 stars$21.93+1.2%$38.91+77.4%+34.6%$3.16B$330.53M-7.95430Short Interest ↑Analyst RevisionXENEXenon Pharmaceuticals2.7476 of 5 stars$38.52-2.8%$56.00+45.4%-13.3%$2.94B$9.43M-13.66210Options VolumeAnalyst RevisionNews CoveragePositive NewsACADACADIA Pharmaceuticals4.0961 of 5 stars$17.57+0.3%$25.25+43.7%-35.8%$2.92B$726.44M22.53510Analyst RevisionVCELVericel1.6592 of 5 stars$59.07+4.8%$62.14+5.2%+39.3%$2.92B$197.52M984.66300MORMorphoSys0.2051 of 5 stars$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Immunovant Alternatives Crinetics Pharmaceuticals Alternatives Avidity Biosciences Alternatives PTC Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Denali Therapeutics Alternatives Xenon Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives Vericel Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COGT) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
